160 related articles for article (PubMed ID: 22029859)
21. SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV.
Dempe S; Stroh-Dege AY; Schwarz E; Rommelaere J; Dinsart C
Int J Cancer; 2010 Jun; 126(12):2914-27. PubMed ID: 19856310
[TBL] [Abstract][Full Text] [Related]
22. Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer.
Neulinger-Muñoz M; Schaack D; Grekova SP; Bauer AS; Giese T; Salg GA; Espinet E; Leuchs B; Heller A; Nüesch JPF; Schenk M; Volkmar M; Giese NA
Viruses; 2021 May; 13(6):. PubMed ID: 34071585
[TBL] [Abstract][Full Text] [Related]
23. Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells.
Heinrich B; Goepfert K; Delic M; Galle PR; Moehler M
Onco Targets Ther; 2013; 6():1119-27. PubMed ID: 23986643
[TBL] [Abstract][Full Text] [Related]
24. Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.
Jennings VA; Scott GB; Rose AMS; Scott KJ; Migneco G; Keller B; Reilly K; Donnelly O; Peach H; Dewar D; Harrington KJ; Pandha H; Samson A; Vile RG; Melcher AA; Errington-Mais F
Mol Ther; 2019 Jun; 27(6):1139-1152. PubMed ID: 31053413
[TBL] [Abstract][Full Text] [Related]
25. Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis.
Lacroix J; Schlund F; Leuchs B; Adolph K; Sturm D; Bender S; Hielscher T; Pfister SM; Witt O; Rommelaere J; Schlehofer JR; Witt H
Int J Cancer; 2014 Feb; 134(3):703-16. PubMed ID: 23852775
[TBL] [Abstract][Full Text] [Related]
26. Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1.
Josupeit R; Bender S; Kern S; Leuchs B; Hielscher T; Herold-Mende C; Schlehofer JR; Dinsart C; Witt O; Rommelaere J; Lacroix J
Viruses; 2016 May; 8(5):. PubMed ID: 27213425
[TBL] [Abstract][Full Text] [Related]
27. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models.
Geletneky K; Kiprianova I; Ayache A; Koch R; Herrero Y Calle M; Deleu L; Sommer C; Thomas N; Rommelaere J; Schlehofer JR
Neuro Oncol; 2010 Aug; 12(8):804-14. PubMed ID: 20299703
[TBL] [Abstract][Full Text] [Related]
28. Through its nonstructural protein NS1, parvovirus H-1 induces apoptosis via accumulation of reactive oxygen species.
Hristov G; Krämer M; Li J; El-Andaloussi N; Mora R; Daeffler L; Zentgraf H; Rommelaere J; Marchini A
J Virol; 2010 Jun; 84(12):5909-22. PubMed ID: 20375165
[TBL] [Abstract][Full Text] [Related]
29. Fluorescence In Situ Hybridization (FISH) Detection of Viral Nucleic Acids in Oncolytic H-1 Parvovirus-Treated Human Brain Tumors.
Kiprianova I; Just A; Leuchs B; Rommelaere J; Angelova AL
Methods Mol Biol; 2020; 2058():295-306. PubMed ID: 31486047
[TBL] [Abstract][Full Text] [Related]
30. Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing.
Goepfert K; Dinsart C; Rommelaere J; Foerster F; Moehler M
Front Oncol; 2019; 9():425. PubMed ID: 31192129
[TBL] [Abstract][Full Text] [Related]
31. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells.
Moehler MH; Zeidler M; Wilsberg V; Cornelis JJ; Woelfel T; Rommelaere J; Galle PR; Heike M
Hum Gene Ther; 2005 Aug; 16(8):996-1005. PubMed ID: 16076257
[TBL] [Abstract][Full Text] [Related]
32. Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas.
Li J; Bonifati S; Hristov G; Marttila T; Valmary-Degano S; Stanzel S; Schnölzer M; Mougin C; Aprahamian M; Grekova SP; Raykov Z; Rommelaere J; Marchini A
EMBO Mol Med; 2013 Oct; 5(10):1537-55. PubMed ID: 24092664
[TBL] [Abstract][Full Text] [Related]
33. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV.
Angelova AL; Aprahamian M; Grekova SP; Hajri A; Leuchs B; Giese NA; Dinsart C; Herrmann A; Balboni G; Rommelaere J; Raykov Z
Clin Cancer Res; 2009 Jan; 15(2):511-9. PubMed ID: 19147756
[TBL] [Abstract][Full Text] [Related]
34. Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry.
Kulkarni A; Ferreira T; Bretscher C; Grewenig A; El-Andaloussi N; Bonifati S; Marttila T; Palissot V; Hossain JA; Azuaje F; Miletic H; Ystaas LAR; Golebiewska A; Niclou SP; Roeth R; Niesler B; Weiss A; Brino L; Marchini A
Nat Commun; 2021 Jun; 12(1):3834. PubMed ID: 34158478
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies.
Angelova AL; Aprahamian M; Balboni G; Delecluse HJ; Feederle R; Kiprianova I; Grekova SP; Galabov AS; Witzens-Harig M; Ho AD; Rommelaere J; Raykov Z
Mol Ther; 2009 Jul; 17(7):1164-72. PubMed ID: 19367260
[TBL] [Abstract][Full Text] [Related]
36. Silencing of Mcl-1 overcomes resistance of melanoma cells against TRAIL-armed oncolytic adenovirus by enhancement of apoptosis.
Tolksdorf B; Zarif S; Eberle J; Hazini A; Dieringer B; Jönsson F; Kreppel F; Kurreck J; Fechner H
J Mol Med (Berl); 2021 Sep; 99(9):1279-1291. PubMed ID: 34028599
[TBL] [Abstract][Full Text] [Related]
37. Anticancer effects of an oncolytic parvovirus combined with non-conventional therapeutics on pancreatic carcinoma cell lines.
Raykov Z; Georgieva PB; Angelova A; Galabov AS; Rommelaere J
Acta Virol; 2009; 53(1):57-60. PubMed ID: 19301953
[TBL] [Abstract][Full Text] [Related]
38. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
[TBL] [Abstract][Full Text] [Related]
39. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
Front Immunol; 2019; 10():1848. PubMed ID: 31440242
[TBL] [Abstract][Full Text] [Related]
40. A Roadmap for the Success of Oncolytic Parvovirus-Based Anticancer Therapies.
Hartley A; Kavishwar G; Salvato I; Marchini A
Annu Rev Virol; 2020 Sep; 7(1):537-557. PubMed ID: 32600158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
